American Portfolios Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

American Portfolios Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.86K	Hold	1,650	–	–	﹤0.01%	2923
2022 Q2	$5K	Hold	1,650	–	–	﹤0.01%	2826
2022 Q1	$11.2K	Hold	1,650	–	–	﹤0.01%	2638
2021 Q4	$13.8K	Hold	1,650	–	–	﹤0.01%	2499
2021 Q3	$12.3K	Hold	1,650	–	–	﹤0.01%	2482
2021 Q2	$11.2K	Hold	1,650	–	–	﹤0.01%	2470
2021 Q1	$16.9K	Sell	1,650 -150	-8%	-$1.64K	﹤0.01%	2156
2020 Q4	$12.6K	Hold	1,800	–	–	﹤0.01%	2007
2020 Q3	$14.7K	Sell	1,800 -250	-12%	-$1.55K	﹤0.01%	1835
2020 Q2	$14.1K	Buy	2,050 +450	+28%	+$2.43K	﹤0.01%	1791
2020 Q1	$7.6K	Buy	1,600 +250	+19%	+$1.44K	﹤0.01%	1919
2019 Q4	$11.8K	Buy	1,350 +750	+125%	+$4.05K	﹤0.01%	1934
2019 Q3	$2K	Hold	600	–	–	﹤0.01%	2517
2019 Q2	$2.97K	Sell	600 -500	-45%	-$2.65K	﹤0.01%	2354
2019 Q1	$6.82K	Hold	1,100	–	–	﹤0.01%	1972
2018 Q4	$3.71K	Hold	1,100	–	–	﹤0.01%	1963
2018 Q3	$7.15K	Hold	1,100	–	–	﹤0.01%	1872
2018 Q2	$8.43K	Buy	+1,100	New	+$15.9K	﹤0.01%	1786

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

American Portfolios Advisors's JNCE Position: Q3 2022 in Review

American Portfolios Advisors held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q3 2022 at 1,650 shares worth $3.86K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

American Portfolios Advisors first reported a position in JNCE in Q2 2018 and has held it in 18 quarters since. The position peaked at $16.9K in Q1 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

American Portfolios Advisors held 1,650 shares of Jounce Therapeutics, Inc. Common Stock worth $3.86K as of Q3 2022.
American Portfolios Advisors left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2923 holding.
American Portfolios Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 18 quarters since.
American Portfolios Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $16.9K in Q1 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.